<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03652805</url>
  </required_header>
  <id_info>
    <org_study_id>101/ 2</org_study_id>
    <nct_id>NCT03652805</nct_id>
  </id_info>
  <brief_title>A Study of IPL344 in the Treatment of ALS Patients</brief_title>
  <acronym>ALS</acronym>
  <official_title>Phase 1/2a, Multi-center, Open-Label, Dose-escalating Study to Assess Safety, Tolerability, and Pharmacokinetics of Intravenously Administered IPL344 for The Treatment of Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunity Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunity Pharma Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, phase 1/2a study, dose escalation, to evaluate&#xD;
      tolerability, safety, and PK of I.V. administered IPL344 in participants with Amyotrophic&#xD;
      Lateral Sclerosis (ALS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to determine the tolerability, safety and PK of IPL344 administered&#xD;
      I.V. once a day for 28 days and to identify the maximum tolerated dose.&#xD;
&#xD;
      All patients enrolled will have a documented history of ALS disease prior to study&#xD;
      enrollment.&#xD;
&#xD;
      Treatment will start with 1.7mg/kg with dose escalation by 0.5 mg/kg every 3-4 days and will&#xD;
      increase to the maximum dose of 3.2mg/kg. Day 1 to Day 28 patients will be on active&#xD;
      treatment.&#xD;
&#xD;
      After completion of 28 treatment days, participants who will choose to continue treatment (at&#xD;
      the investigator's discretion), will be enrolled in a follow-up study. Participants that&#xD;
      discontinue treatment after Day 28 will be followed up by a nurse phone call and return to&#xD;
      the clinic for a final visit on Day 56 from the first dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">August 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs) and serious adverse events (SAEs) Reporting</measure>
    <time_frame>(up-to Day 56)</time_frame>
    <description>All AEs will be recorded, whether considered minor or serious, drug-related or not</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Study treatment duration (Day 1 -28 days)</time_frame>
    <description>Dose defined as the highest dose with no Dose Limiting Toxicity (DLT). DLT will be defined as a Grade ≥ 3 toxicity per participant according to Common Terminology Criteria for Adverse Events (CTCAE v5.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile - Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-Dose and 5, 10, 20, 30, 45, 60 and 120 minutes after dosing</time_frame>
    <description>Blood will be collected for PK testing on Day 1 prior to and after first dose and on each dose-escalation administration day and on Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile - Area Under the Curve (AUC)</measure>
    <time_frame>Pre-Dose and 5, 10, 20, 30, 45, 60 and 120 minutes after dosing</time_frame>
    <description>Blood will be collected for PK testing on Day 1 prior to and after first dose and on each dose-escalation administration day and on Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile - time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>Pre-Dose and 5, 10, 20, 30, 45, 60 and 120 minutes after dosing</time_frame>
    <description>Blood will be collected for PK testing on Day 1 prior to and after first dose and on each dose-escalation administration day and on Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) profile - apparent terminal exponential half-life (T1/2)</measure>
    <time_frame>Pre-Dose and 5, 10, 20, 30, 45, 60 and 120 minutes after dosing</time_frame>
    <description>Blood will be collected for PK testing on Day 1 prior to and after first dose and on each dose-escalation administration day and on Day 28</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory: Biomarker testing</measure>
    <time_frame>up-to Day 56</time_frame>
    <description>Blood samples for exploratory Biomarkers (Biobanking)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: Anti-Drug Antibody (ADA) testing</measure>
    <time_frame>up-to Day 56</time_frame>
    <description>Blood samples for Anti-Drug Antibody (Biobanking)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory: identify a marker based on the mechanism of action (MOA)</measure>
    <time_frame>up-to Day 56</time_frame>
    <description>Blood samples for future PD (Biobanking)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in ALS disease progression</measure>
    <time_frame>up-to day 56</time_frame>
    <description>ALS functional rating scale-Revised (ALSFRS-R) - Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in Pulmonary Function</measure>
    <time_frame>up-to day 56</time_frame>
    <description>Measured by Vital Capacity (VC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in Muscle strength</measure>
    <time_frame>up-to day 56</time_frame>
    <description>Assessed by using a quantitative strength testing tool, Hand Held Dynamometry (HHD)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in Anti-Depression effect</measure>
    <time_frame>up-to day 56</time_frame>
    <description>Evaluated by ALS Depression Inventory (ADI-12) - questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from baseline in Anti-Depression effect</measure>
    <time_frame>up-to day 56</time_frame>
    <description>the Hospital Anxiety and Depression Scale (HADS) - questionnaire</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>IPL344</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IPL344 will be administered Intravenously on a daily basis. The dose range of IPL344 is 1.7-3.2 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IPL344</intervention_name>
    <description>The study is designed to determine the tolerability, safety and PK of IPL344 administered I.V. once a day for 28 days and to identify the maximum tolerated dose.&#xD;
All patients enrolled will have a documented history of ALS disease prior to study enrollment.&#xD;
Treatment will start with 1.7mg/kg with dose escalation by 0.5 mg/kg every 3-4 days and will increase to the maximum dose of 3.2mg/kg. Day 1 to Day 28 patients will be on active treatment.&#xD;
After completion of 28 treatment days, participants who will choose to continue treatment (at the investigator's discretion), will be enrolled in a follow-up study. Participants that discontinue treatment after Day 28 will be followed up by a nurse phone call and return to the clinic for a final visit on Day 56 from the first dose.</description>
    <arm_group_label>IPL344</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female participants ages ≥18 to 80 years&#xD;
&#xD;
          2. Consenting participants fulfilling the El Escorial criteria for probable and definite&#xD;
             ALS (sporadic and familial)&#xD;
&#xD;
          3. Participant has ALSFRS-R score &gt;20, the latest ALSFRS-R test should be no more than 6&#xD;
             weeks before screening visit, AND:&#xD;
&#xD;
               1. a disease progression rate greater than 0.55 ALSFRS-R point per month on average,&#xD;
                  over at least 4 months, prior to the latest ALSFRS-R test OR&#xD;
&#xD;
               2. a decline of at least 3 points in ALSFRS-R score within the last 4 months prior&#xD;
                  to the latest ALSFRS-R test&#xD;
&#xD;
          4. Previous data of Force Vital Capacity (FVC) of ≥60% at least 3 months before screening&#xD;
             and not more than 12 months.&#xD;
&#xD;
          5. Written informed consent consistent with ICH-GCP and local laws, signed prior to any&#xD;
             study procedures being performed.&#xD;
&#xD;
          6. BMI 18.5 to 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg.&#xD;
&#xD;
          7. If taking riluzole or edaravone, the participant must be on a stable dose for ≥30 days&#xD;
             prior to Day 1 and expected to remain at that dose until the final study visit.&#xD;
&#xD;
          8. Medically able to undergo the study procedures, and to adhere to the visit schedule at&#xD;
             the time of study entry.&#xD;
&#xD;
          9. Medically is able and willing to undergo placement and maintain a central venous&#xD;
             catheter as determined by the investigator.&#xD;
&#xD;
         10. Participant has a competent caregiver or qualified individual who can and will be&#xD;
             responsible for the administration of study drug and reporting home activities.&#xD;
&#xD;
         11. Geographic accessibility to the study site&#xD;
&#xD;
         12. Females must not be lactating or pregnant at Screening, as documented by a negative&#xD;
             beta-human chorionic gonadotropin [ß-hCG] (or human chorionic gonadotropin [hCG].&#xD;
&#xD;
         13. Women of child-bearing potential or males whose partners are women of child-bearing&#xD;
             potential use an effective method of contraception throughout the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Concurrent therapy that, in the PI's opinion, would interfere with the evaluation of&#xD;
             the safety or efficacy of the study medication.&#xD;
&#xD;
          2. Co-existing psychiatric disorder excluding a depression disorder occurred after ALS&#xD;
             diagnosis.&#xD;
&#xD;
          3. Participant is a respiratory dependent.&#xD;
&#xD;
          4. Subjects with a significant pulmonary disorder not attributed to ALS.&#xD;
&#xD;
          5. Slow Vital Capacity (SVC) &lt;60.&#xD;
&#xD;
          6. Presence of any other condition or circumstance that, in the judgment of the&#xD;
             Investigator, might contraindicate or increase the risk to the participant or decrease&#xD;
             the chance of obtaining satisfactory data to achieve the objectives of the study.&#xD;
&#xD;
          7. History of HIV, positive HBV or HCV serology.&#xD;
&#xD;
          8. Participants suffering from significant cardiac, or any other disease that may&#xD;
             endanger the participant or interfere with the ability to interpret the results.&#xD;
&#xD;
          9. A participant with active infections.&#xD;
&#xD;
         10. Documented active cancer.&#xD;
&#xD;
         11. Treatment with another investigational drug, biological agent, or device within 2&#xD;
             months of the first dose, or investigational cell therapy within 6 months of the first&#xD;
             dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marc Gotkine, M.D.</last_name>
    <phone>+972 2 6778899</phone>
    <email>marc@gotkine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Center -Motor Neuron Disease Clinic</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Gotkune, M.D.</last_name>
      <phone>+972 2 6778899</phone>
      <email>marc@gotkine.com</email>
    </contact>
    <investigator>
      <last_name>Marc Kotkine, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

